{
  "id": 11076524,
  "title": "Lunit Plans Five AI Biomarker Abstracts for ESMO",
  "url": "https://urgent.news/2026/10/01/lunit-plans-five-ai-biomarker-abstracts-for-esmo",
  "topic": "ai",
  "section": "AI",
  "published": "2026-10-01T01:36:52.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=277998"
  },
  "original_language": "en",
  "account": "Lunit, an AI biomarker platform, has announced its participation in the 2026 European Society for Medical Oncology (ESMO 2026) conference in Madrid, Spain, from October 23 to 27. The company will present five research abstracts utilizing its AI technology. One study focuses on PD-L1 evaluation using surgical specimens from non-small cell lung cancer patients, comparing Lunit SCOPE's results with those of a pathologist. The company will also showcase its involvement in the AIforHER project led by the French cancer center ICO, which aims to develop optimal diagnostic models for breast cancer HER2 analysis. Furthermore, Lunit will present findings from studies analyzing the prognostic significance of endothelial cells and KRAS mutation subtypes in pancreatic ductal adenocarcinoma, as well as the prognostic value of tertiary lymphoid structures for pan-cancer patients who have received immunotherapy. CEO Suh Beom-seok emphasized that the company will share global research achievements across various cancer types at the conference, aiming to contribute to customized treatment strategies for patients by accurately analyzing tumors and their surrounding environments.",
  "summary": "Lunit announced on Oct. 1 that it will participate in the '2026 European Society for Medical Oncology (ESMO 2026)' held in Madrid, Spain, from Oct. 23 to 27 to present five research abstracts utilizing its AI biomarker platform, 'Lunit SCOPE'.Lunit will unveil a PD-L1 evaluation study utilizing surg",
  "key_points": [
    "Lunit to present five AI biomarker abstracts at ESMO 2026 in Madrid.",
    "Study compares Lunit SCOPE s PD-L1 evaluation with pathologist results.",
    "Lunit involved in AIforHER project for breast cancer HER2 analysis."
  ],
  "editors_take": "Lunit's presentation of five AI biomarker abstracts at ESMO 2026 underscores its growing influence in oncology research and its push for integrating AI into personalized cancer treatment strategies.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}